Glaukos Corporation (GKOS) Eye Treatment Epioxa Poised for Strong Market Uptake, Says Stifel

Glaukos Corporation (NYSE:GKOS) ranks among the best medical device stocks to invest in. As Glaukos Corporation (NYSE:GKOS) nears the October 20 PDUFA date for its Epioxa medication, Stifel reaffirmed its Buy rating and $115 price target for the company on October 8. According to the firm’s survey of 27 corneal cross-linking (CXL) ophthalmologists, Epioxa’s uptake and volume projections seem to be robust.

The survey’s findings confirm Stifel’s prediction that the medication will swiftly take up the majority of CXL operation volume and boost market expansion. A potential obstacle that Glaukos Corporation (NYSE:GKOS) management had previously identified is mitigated by Stifel’s survey, which also shows minimal CXL patient warehousing before Epioxa’s debut. This finding reinforced the firm’s upward bias on Corneal Health revenue in the second half of 2025 and 2026.

Glaukos Corporation (NYSE:GKOS) is a medical technology company that focuses on developing novel treatments for eye diseases such as glaucoma, corneal problems, and retinal diseases. The company creates micro-invasive surgical instruments and drug delivery systems to enhance patient outcomes.

While we acknowledge the potential of GKOS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.